Related references
Note: Only part of the references are listed.Developmental Changes in the Expression and Function of Cytochrome P450 3A Isoforms: Evidence from In Vitro and In Vivo Investigations
Ibrahim Ince et al.
CLINICAL PHARMACOKINETICS (2013)
First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development
Ashley Strougo et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2012)
A Semiphysiological Population Model for Prediction of the Pharmacokinetics of Drugs under Liver and Renal Disease Conditions
Ashley Strougo et al.
DRUG METABOLISM AND DISPOSITION (2011)
Mechanism-based concepts of size and maturity in pharmacokinetics
B. J. Anderson et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2008)
Physiology-Based Simulations of a Pathological Condition Prediction of Pharmacokinetics in Patients with Liver Cirrhosis
Andrea N. Edginton et al.
CLINICAL PHARMACOKINETICS (2008)
Facilitation of drug evaluation in children by population methods and modelling
Michel Tod et al.
CLINICAL PHARMACOKINETICS (2008)
Ontogeny of human hepatic cytochromes P450
Ronald N. Hines
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY (2007)
Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children
Trevor N. Johnson et al.
CLINICAL PHARMACOKINETICS (2006)
A mechanistic approach for the scaling of clearance in children
Andrea N. Edginton et al.
CLINICAL PHARMACOKINETICS (2006)
57 varieties: the human cytochromes P450
DFV Lewis
PHARMACOGENOMICS (2004)
Evidence of significant contribution from CYP3A5 to hepatic drug metabolism
WL Huang et al.
DRUG METABOLISM AND DISPOSITION (2004)
Developmental expression of the major human hepatic CYP3A enzymes
JC Stevens et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Share Paper
